Tempus AI (TEM) drew fresh investor attention after announcing a collaboration with Angiosarcoma Awareness, Inc. focused on one of the largest molecular datasets for this rare cancer, tying its AI platform directly to high impact research.

Against this backdrop, Tempus AI’s recent research collaborations and validation work on its ECG-AF software have arrived during a period of strong momentum. The company has recorded a 30 day share price return of 29.81% and a 90 day share price return of 27.42%. However, the year to date share price return is down 3.35%, and the 1 year total shareholder return is down 1.15% from a latest share price of $60.27.

If this kind of healthcare data story interests you, it could be worth widening your watchlist through our screener featuring 40 healthcare AI stocks.

After a sharp 30 day move and a share price of $60.27, sentiment around Tempus AI already reflects strong interest in its healthcare data and AI story. The key question is whether there is still a buying opportunity here, or if the market is already pricing in future growth.

Most Popular Narrative: 8.5% Undervalued

According to the most widely followed Tempus AI narrative, a fair value of $65.90 sits above the recent $60.27 share price. This frames the stock as modestly undervalued and places emphasis on the long term potential of its data platform.

Tempus AI isn't simply an AI software business (not another ChatBot). It is building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.

Want to understand what kind of revenue mix, margin profile, and future valuation multiple this narrative is built on? The fair value hinges on a specific growth runway, rising profitability, and a premium earnings multiple that together suggest a very different earnings power than today.

Result: Fair Value of $65.90 (UNDERVALUED)

However, this Tempus AI narrative could be challenged if the company struggles to reach sustained profitability or if expectations for healthcare AI adoption prove too optimistic.

Another View on Tempus AI’s Valuation

There is a twist when you look at Tempus AI through its revenue multiple. The stock trades on a P/S of 7.9x compared with 4.7x for peers and 4x for the wider US Life Sciences industry, even though the current ratio already sits at the fair ratio of 7.9x. That kind of premium can signal quality, but it can also limit upside if growth or profitability slip, so which way do you think the story breaks from here?

To see how this revenue multiple compares with the underlying assumptions, including the fair ratio the market could move toward, take a closer look at our valuation breakdown, starting with See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment already mixed around Tempus AI, with both concerns and optimism in play, it makes sense to move quickly, compare the data points, and shape your own view by reviewing the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Tempus AI?

Tempus AI may be front of mind today, but you do not want your next opportunity to slip past. Put a few minutes into widening your watchlist with focused screens.

• Target potential upside by scanning for companies that combine quality with attractive pricing using our 44 high quality undervalued stocks.
• Prioritise resilience by zeroing in on companies with lower risk profiles through the 74 resilient stocks with low risk scores.
• Hunt for tomorrow's potential standouts before they hit the spotlight with the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.